Akamatsu H, Toi Y, Hayashi H, et al. - In patients suffering from lung adenocarcinoma with EGFR (epidermal growth factor receptor) T790M mutation, researchers investigated whether osimertinib plus bevacizumab has efficacy and safety vs osimertinib alone. This study involved advanced lung adenocarcinoma cases that showed progression with prior EGFR-tyrosine kinase inhibitor (TKI) therapy (other than third-generation TKI) and acquired EGFR T790M mutation. Patients were randomly assigned to osimertinib plus bevacizumab or osimertinib alone in a 1:1 ratio in the phase 2. Findings revealed that progression-free survival was not prolonged by osimertinib plus bevacizumab in patients with advanced lung adenocarcinoma with EGFR T790M mutation.